Tags

Type your tag names separated by a space and hit enter

Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients.

Abstract

OBJECTIVE

This open-label study was performed to evaluate the efficacy and safety of oral treatment with the antioxidant alpha-lipoic acid (ALA, thioctic acid) in Korean diabetic patients with distal symmetric polyneuropathy (DSP).

SUBJECTS AND METHODS

Thioctic acid was administered orally using 600 mg once daily for 8 weeks in 61 diabetic patients with symptomatic polyneuropathy. Neuropathic symptoms (pain, burning sensation, paresthesia, and numbness) were scored at baseline as well as at 4 and 8 weeks following treatment. In addition, neurological assessment was carried out before and after 8 weeks of treatment, and an overall evaluation was performed at the end of treatment. The primary endpoint was the response rate after 8 weeks of treatment, defined as an improvement in the Total Symptom Score (TSS) of > or =30%.

RESULTS

Efficacy was evaluated in 38 patients who had completed the study according to the protocol. Safety was evaluated in all 61 patients who had taken the study medication. Fasting blood glucose and HbA(1)c did not change during the study. The response rate after 8 weeks was 71.4%. At 4 weeks, the response rate was 47.4%. The TSS significantly decreased at 4 weeks, which decreased further at 8 weeks (P<.05). All the individual scores for neuropathic symptoms (pain, burning sensation, paresthesia, and numbness) were also significantly reduced at 4 weeks and further decreased at 8 weeks (P<.05). The duration of diabetes, severity and duration of diabetic polyneuropathy, and all the other demographic and metabolic parameters did not demonstrate an effect on the response rate. The parameters of neurological assessment (ankle reflexes, pin-prick test, 10-g monofilament test) and quantitative sensory tests (vibration, warm and cold sensation) were not influenced by 8 weeks of treatment with 600 mg of oral thioctic acid per day. Overall efficacy rated as "good/fair" was 86.8% by the physician and 76.3% by the patients at the end of an 8-week treatment period. Eleven episodes (18.0%) of adverse events (possibly, probably, definitely related) were reported in seven patients (11.5%).

CONCLUSION

These findings indicate that oral treatment with thioctic acid at a dose of 600 mg/day for 8 weeks improved symptoms of polyneuropathy in Korean diabetic patients without causing serious adverse events.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine, College of Medicine, Gyeongsang Institute of Health Science, Gyeongsang National University, Jinju, South Korea.

    ,

    Source

    MeSH

    Antioxidants
    Diabetic Neuropathies
    Female
    Humans
    Korea
    Male
    Middle Aged
    Safety
    Thioctic Acid

    Pub Type(s)

    Clinical Trial
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    15120701

    Citation

    Hahm, Jong Ryeal, et al. "Clinical Experience With Thioctacid (thioctic Acid) in the Treatment of Distal Symmetric Polyneuropathy in Korean Diabetic Patients." Journal of Diabetes and Its Complications, vol. 18, no. 2, 2004, pp. 79-85.
    Hahm JR, Kim BJ, Kim KW. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J Diabetes Complicat. 2004;18(2):79-85.
    Hahm, J. R., Kim, B. J., & Kim, K. W. (2004). Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. Journal of Diabetes and Its Complications, 18(2), pp. 79-85.
    Hahm JR, Kim BJ, Kim KW. Clinical Experience With Thioctacid (thioctic Acid) in the Treatment of Distal Symmetric Polyneuropathy in Korean Diabetic Patients. J Diabetes Complicat. 2004;18(2):79-85. PubMed PMID: 15120701.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. AU - Hahm,Jong Ryeal, AU - Kim,Byung-Joon, AU - Kim,Kwang-Won, PY - 2002/12/30/received PY - 2003/03/03/revised PY - 2003/03/06/accepted PY - 2004/5/4/pubmed PY - 2004/12/16/medline PY - 2004/5/4/entrez SP - 79 EP - 85 JF - Journal of diabetes and its complications JO - J. Diabetes Complicat. VL - 18 IS - 2 N2 - OBJECTIVE: This open-label study was performed to evaluate the efficacy and safety of oral treatment with the antioxidant alpha-lipoic acid (ALA, thioctic acid) in Korean diabetic patients with distal symmetric polyneuropathy (DSP). SUBJECTS AND METHODS: Thioctic acid was administered orally using 600 mg once daily for 8 weeks in 61 diabetic patients with symptomatic polyneuropathy. Neuropathic symptoms (pain, burning sensation, paresthesia, and numbness) were scored at baseline as well as at 4 and 8 weeks following treatment. In addition, neurological assessment was carried out before and after 8 weeks of treatment, and an overall evaluation was performed at the end of treatment. The primary endpoint was the response rate after 8 weeks of treatment, defined as an improvement in the Total Symptom Score (TSS) of > or =30%. RESULTS: Efficacy was evaluated in 38 patients who had completed the study according to the protocol. Safety was evaluated in all 61 patients who had taken the study medication. Fasting blood glucose and HbA(1)c did not change during the study. The response rate after 8 weeks was 71.4%. At 4 weeks, the response rate was 47.4%. The TSS significantly decreased at 4 weeks, which decreased further at 8 weeks (P<.05). All the individual scores for neuropathic symptoms (pain, burning sensation, paresthesia, and numbness) were also significantly reduced at 4 weeks and further decreased at 8 weeks (P<.05). The duration of diabetes, severity and duration of diabetic polyneuropathy, and all the other demographic and metabolic parameters did not demonstrate an effect on the response rate. The parameters of neurological assessment (ankle reflexes, pin-prick test, 10-g monofilament test) and quantitative sensory tests (vibration, warm and cold sensation) were not influenced by 8 weeks of treatment with 600 mg of oral thioctic acid per day. Overall efficacy rated as "good/fair" was 86.8% by the physician and 76.3% by the patients at the end of an 8-week treatment period. Eleven episodes (18.0%) of adverse events (possibly, probably, definitely related) were reported in seven patients (11.5%). CONCLUSION: These findings indicate that oral treatment with thioctic acid at a dose of 600 mg/day for 8 weeks improved symptoms of polyneuropathy in Korean diabetic patients without causing serious adverse events. SN - 1056-8727 UR - https://www.unboundmedicine.com/medline/citation/15120701/Clinical_experience_with_thioctacid__thioctic_acid__in_the_treatment_of_distal_symmetric_polyneuropathy_in_Korean_diabetic_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056872703000333 DB - PRIME DP - Unbound Medicine ER -